提尔德拉基祖马布与局部哈尔西诺尼德0.1%药膏联合使用,用于治疗中度至重度的斑块性牛皮
Journal of drugs in dermatology : JDD
|August 9, 2023
概括
提尔德拉基祖马布与西诺尼德药膏相结合,有效治疗中度至重度的斑块性牛皮. 这种组合疗法改善了皮肤覆盖和生活质量,对单独的蒂尔德拉基祖马布反应不足的患者的不良反应最小.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病.
- 蒂尔德拉基祖马布是一种用于治疗牛皮的素-23抑制剂.
- 局部皮质类固醇通常用于管理牛皮症状.
研究的目的:
- 为了评估蒂尔德拉基祖马布与局部西诺尼德药膏结合的有效性和安全性.
- 评估这种联合治疗对牛皮病严重程度和患者生活质量的影响.
主要方法:
- 一项前性开放性研究,涉及中度至重度斑块性牛皮的成年患者.
- 患者在第0周,第4周和第16周接受了蒂德拉基祖马布 (100毫克).
- 在第16周,向患有身体表面积 (BSA) >3%的患者施用了0.1%的辅助局部类.
主要成果:
- 在BSA,牛皮区域和严重性指数 (PASI) 75,以及医生的全球评估 (PGA) 中观察到显著改善.
- 组合疗法导致持续的皮肤清除和提高生活质量.
- 不良事件很少发生,没有严重事件或因不良事件而停止治疗.
结论:
- 提尔德拉基祖马布加上局部哈尔诺因德药膏是一种安全有效的治疗选择.
- 这种组合治疗对中度至重度斑块性牛皮的患者有益,这些患者对蒂尔德拉基祖马布单一治疗反应不充分.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
299
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
299
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244


